Choroidal naevus regression associated with PD-1 inhibitor monotherapy for metastatic cutaneous malignant melanoma

被引：2
|
作者：
Krohn, Jorgen [1 ,2 ]
Hanken, Geir [3 ]
Herlofsen, Oluf [4 ]
机构：
[1] Univ Bergen, Dept Clin Med, Sect Ophthalmol, Bergen, Norway
[2] Haukeland Hosp, Dept Ophthalmol, N-5021 Bergen, Norway
[3] More & Romsdal Hosp Trust, Alesund Hosp, Dept Ophthalmol, Alesund, Norway
[4] More & Romsdal Hosp Trust, Alesund Hosp, Dept Oncol, Alesund, Norway
来源：
ACTA OPHTHALMOLOGICA | 2020年 / 98卷 / 02期
关键词：
D O I：
10.1111/aos.14237
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
引用
收藏
页码：E262 / E264
页数：3
相关论文
共 50 条
  • [41] Hypothyroidism-associated Myopathy after Immunotherapy with PD-1 Antibodies: Report of Patients with metastatic Melanoma
    Rausch, L.
    Gutzmer, R.
    Satzger, I
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 : 24 - 24
  • [42] Germline variation in PDCD1 is associated with survival in metastatic melanoma after anti-PD-1 monotherapy
    De With, M.
    Hurkmans, D. P.
    Oomen-de Hoop, E.
    Lalouti, A.
    Bins, S.
    El Bouazzaoui, S.
    Debets, R.
    Aerts, J. G.
    Van Schaik, R. H. N.
    Mathijssen, R. H.
    Van der Veldt, A. A. M.
    ANNALS OF ONCOLOGY, 2020, 31 : S758 - S758
  • [43] In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma
    Babacic, Haris
    Lehtio, Janne
    de Coana, Yago Pico
    Pernemalm, Maria
    Eriksson, Hanna
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [44] Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor
    Escandon, Julia
    Peacock, Stephanie
    Trabolsi, Asaad
    Thomas, David B.
    Layka, Ayman
    Lutzky, Jose
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [45] Monotherapy of PD-1 Inhibitor Camrelizumab Reverses Advanced Lung Squamous Cell Carcinoma with Low PD-1 Expression: A Case Report
    Zheng, Xiufen
    Li, Jue
    Gao, Zhenqing
    Fang, Yi
    Feng, Zikai
    CASE REPORTS IN ONCOLOGY, 2024, 17 (01): : 928 - 934
  • [46] Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
    Zaretsky, Jesse M.
    Garcia-Diaz, Angel
    Shin, Daniel S.
    Escuin-Ordinas, Helena
    Hugo, Willy
    Hu-Lieskovan, Siwen
    Torrejon, Davis Y.
    Abril-Rodriguez, Gabriel
    Sandoval, Salemiz
    Barthly, Lucas
    Saco, Justin
    Moreno, Blanca Homet
    Mezzadra, Riccardo
    Chmielowski, Bartosz
    Ruchalski, Kathleen
    Shintaku, I. Peter
    Sanchez, Phillip J.
    Puig-Saus, Cristina
    Cherry, Grace
    Seja, N. P. Elizabeth
    Kong, Xiangju
    Pang, Jia
    Berent-Maoz, Beata
    Comin-Anduix, Begona
    Graeber, Thomas G.
    Tumeh, Paul C.
    Schumacher, Ton N. M.
    Lo, Roger S.
    Ribas, Antoni
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (09): : 819 - 829
  • [47] Clinical Outcomes in Metastatic Uveal Melanoma Treated With PD-1 and PD-L1 Antibodies
    Algazi, Alain P.
    Tsai, Katy K.
    Shoushtari, Alexander N.
    Munhoz, Rodrigo R.
    Eroglu, Zeynep
    Piulats, Josep M.
    Ott, Patrick A.
    Johnson, Douglas B.
    Hwang, Jimmy
    Daud, Adil I.
    Sosman, Jeffrey A.
    Carvajal, Richard D.
    Chmielowski, Bartosz
    Postow, Michael A.
    Weber, Jeffrey S.
    Sullivan, Ryan J.
    CANCER, 2016, 122 (21) : 3344 - 3353
  • [48] Effect of antibiotic exposure in patients with metastatic melanoma treated with PD-1 inhibitor or CTLA-4 inhibitor or a combination of both.
    Kapoor, Vidit
    Runnels, Juliana
    Boyce, Tawny
    Pankratz, V. Shane
    Rixe, Olivier
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [49] Combination of Denosumab and an Immunotherapy with PD-1 Inhibitors - a retrospective Analysis of 29 Patients with metastatic malignant Melanoma and Bone Metastasis
    Angela, Y.
    Haferkamp, S.
    Weishaupt, C.
    Ugurel, S.
    Becker, J. C.
    Oberndoerfer, F.
    Alar, V
    Satzger, I
    Gutzmer, R.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2018, 16 : 27 - 28
  • [50] Keratoacanthoma and Cutaneous Squamous Cell Carcinoma With PD-1 and PD-L1 Inhibitor Use
    Aggarwal, Pushkar
    Clark, Denise
    Shah, Aatman
    Rismiller, Kyle
    Neltner, Scott A.
    JAMA DERMATOLOGY, 2024, 160 (05) : 573 - 575
12345